Inspire Pharmaceuticals initiates Phase III dry eye trial
ISPH | Quote | Chart | News | PowerRating -- Inspire Pharmaceuticals has reached agreement with the FDA through a special protocol assessment on the design of a Phase III clinical trial for Prolacria 2% for the treatment of dry eye disease and has recently initiated enrollment in the trial.
Based on the special protocol assessment agreement (SPA), Inspire has initiated a Phase III, randomized, placebo-controlled, environmental clinical trial to evaluate the efficacy and safety of Prolacria in approximately 450 subjects with dry eye who have a fluorescein staining score of three in the central region of the cornea at baseline, using the National Eye Institute (NEI) scale of zero to three. Subjects will be randomized to Prolacria or placebo administered as eye drops four times daily for six weeks at approximately 60 US and Canadian sites.
The agreed upon primary efficacy endpoint is the proportion of subjects receiving Prolacria that achieve clearing of fluorescein staining of the central region of the cornea in the study eye (a score of zero on the NEI scale) at the six-week trial endpoint, compared to those receiving placebo.
The FDA indicated, as part of the SPA review process, that even if this trial is successful, the FDA's review of Prolacria will also take into account the robustness of the trial results, that a surrogate endpoint was used, the results from previous Prolacria trials and the overall risk/benefit.
Christy Shaffer, president and CEO of Inspire, said: "Our decision to continue development of Prolacria is based on a number of factors, including: the dry eye market is large and growing, with only one commercially available prescription product; our analysis of related Prolacria historical data in the central region of the cornea; and the length and estimated costs of this trial are reasonable relative to the financial opportunity."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
For full details on Inspire Pharmaceuticals (ISPH) ISPH. Inspire Pharmaceuticals (ISPH) has Short Term PowerRatings at TradingMarkets. Details on Inspire Pharmaceuticals (ISPH) Short Term PowerRatings is available at This Link.
- SmarTrend's Candlestick Scanner Detects Bullish Piercing Line Pattern for Inspire Pharmaceuticals (ISPH) - 02/08/10
- Inspire Pharmaceuticals, Inc. (ISPH) Corporate Event Announcement Notice - 02/04/10
- Inspire Announces Webcast of Presentation at BIO CEO Conference - 02/04/10
- Inspire Pharmaceuticals, Inc. (ISPH) Corporate Event Announcement Notice - 02/03/10
- America's Pharmaceutical Research Companies Donate $35 Million to Relief Efforts in Haiti; More Help Coming - 02/03/10
- More News >>
